Idexx announces product updates, staff changes

Idexx has made improvements to several of its products to make it easier for veterinarians to accurately diagnose their patients.

The manufacturer announced updates to its SediVue Dx Urine Sediment Analyzer, Catalyst Dx and Catalyst One analyzers, as well as the Web PACS imaging software.

Idexx’s Sedivue Dx Urine Sediment Analyzer has been updated with an advanced bacteria identification feature so doctors can get definitive results from the test. The artificial intelligence-based software uses a database of 350 million veterinary patient-generated images to improve its identification capabilities.

That update will be available in March.

The Catalyst tests, which have long been geared toward kidney health, have been updated with the Catalyst Bile Acids Test, a real-time test of animals’ liver function. Bile acid testing helps veterinarians determine their patients’ liver function when other indicators show possible malfunction.

That update will be available for North American and select European countries in March.

And finally, the Web PACS diagnostic imaging software has been updated with an artificial intelligence function to help vets sort radiographs efficiently to speed up diagnosis. The software automatically corrects image orientation and sorts images by body part, making it easier for doctors to work with unpredictable behavior from their animal patients. The new sorting function can help doctors shave off as much as 25% of the time they spend analyzing images, according to Idexx.

That update will be available to customers by the end of the first quarter, according to the announcement.

In other news, Idexx announced the promotion of five executives in its companion animal group. These changes come soon after Jay Mazelsky took over as president and CEO of the company.

James Polewaczyk, who has led Idexx’s North America commercial operations for several years, will take over the role of chief commercial officer and executive vice president, overseeing companion animal group commercial operations around the world.

“We have a deep and talented leadership team at Idexx, and with our enhanced organizational structure, we are confident that Idexx is well-positioned to drive continued market development and further adoption of diagnostics,” Mazelsky said. “We see tremendous opportunity for growth with a global addressable companion animal diagnostics market opportunity of over $30 billion, supported by the continued strengthening of the pet-owner bond, favorable demographic trends and improving standard of care.”